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Background: Reduced Bone Mass Density (BMD) is frequent in Cystic Fibrosis (CF). Potentially, other genes than the Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) gene may contribute to the bone phenotype variability in CF patients.
Methods: Four candidate genes likely associated with BMD variability were studied: the vitamin D receptor (VDR) gene, the estrogen receptor
alpha (ESR1), the calcitonin receptor (CALCR) and the type I alpha 1 collagen (COL1A1) gene. A complete bone and CF evaluation was
obtained for 82 subjects (39 m, 43 f): 15 had normal BMD (group 1), 46 were osteopenic (group 2), and 21 were osteoporotic (group 3).
Results: No statistical difference was found among the three groups for age, sex, pancreatic status, and vertebral fractures, nor for any of the
biochemical markers.Weight, BodyMass Index (BMI), and FEV1, scored significantly worse in the two groups with the lowest T score. The CFTR
mutations R1162X and F508del were more frequent in patients with lower BMD ( p=0.044 and p=0.071). There was no significant difference in
the distribution of the fivemarker genotypes among the 3 groups defined according to the unadjusted or adjusted (BMI and FEV1)BMDT score.No
significant correlation was found between the VDR, CALCR, or COL1A1 gene polymorphisms and reduced BMD values. The individual ESR1
PvuII-XbaI haplotype C–A is associated to elevated u-calcium levels whereas the haplotype T–A is associated to lower values ( p=0.00251).
Conclusions: There was no evidence that the genes under study, with the possible exception of ESR1 gene variants, may modulate bone
phenotype in CF.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Osteoporosis; Modifier genes1. Introduction
Cystic Fibrosis (CF) is the most common severe autoso-
mal recessive disease in the caucasian population, and it is
caused by mutations of the CF Transmembrane Regulator
(CFTR) gene [1]. The CFTR gene codes for a protein located
in the apical cells of the ductal epithelium in the lung,
pancreas, gallbladder, intestine, liver, salivary and sweat
glands, and the reproductive tract [2]. Such wide distribution
accounts for the multi-organ involvement of the disease.1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.03.008
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E-mail address: carlo.castellani@azosp.vr.it (C. Castellani).In the fifties few childrenwith CF lived to school age, but in
the latest four decades early recognition, centralized care in
dedicated CF Centers, and new and more aggressive treatment
have remarkably improved the survival of patients. The
proportion of adult subjects is constantly increasing [3], and
today, in the USA, the median age of survival extends into the
early 30s [4]. Such increased longevity implies the rise of a
growing number of long-term complications, previously only
occasionally detected. One of these complications is low bone
mineral density (BMD), and the consequent increased fracture
risk. Several studies showed that reduced BMD is frequent in
adult CF, with osteopenia and osteoporosis, respectively in
38% and 13% [5], 34% and 27% [6], and either osteopenia or
osteoporosis in 66% of patients [7].5 (2006) 229 – 235ed by Elsevier B.V. All rights reserved.
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poor nutritional status, calcium, vitamin D and vitamin K
deficiencies, inflammation associated with lung disease,
delayed puberty, hypogonadism, little physical activity, and
medications, mainly corticosteroids [8].
However, BMD is a complex trait, and can be modulated
by genetic factors other than the CFTR gene. As a matter of
fact, hereditary traits account for 70% of an individual_s
peak bone mass [9]. Twin and family studies, as well as
association studies in unrelated individuals, have evaluated
several polymorphic markers associated with low BMD and
increased risk of fractures [10,11].
In this study we selected 5 polymorphic markers of 4
candidate genes that have been described to be involved in
bone density variability.
– The vitamin D receptor (VDR) gene is by far one of the
most widely investigated osteoporosis marker. The
chosen polymorphism was a FokI RFLP at the transla-
tion initiation site that causes a change in the predicted
protein sequence. The genotype termed ff (i.e. TT, in the
nomenclature used in this work) has been associated to
lower BMD values in American women of various ethnic
backgrounds [12].
– The estrogen receptor alpha gene (ESR1) has been
investigated extensively with conflicting results presum-
ably because of population admixture and/or linkage
disequilibrium of the polymorphic markers with differ-
ent causative alleles in various populations [13]. In the
present work, two well-known ESR1 intronic poly-
morphisms (XbaI and PvuII) were studied.
– The calcitonin receptor (CALCR) gene has been tested
by an intragenic AluI polymorphism, which causes an
aminoacid substitution (pro-leu) in the citosolic domain
of the protein [14]. A significant association of the CC
genotype with low BMD values was found in both
women and men in case-control studies [15–17].
– The type I alpha 1 collagen (COL1A1) gene, and a G>T
dymorphism which affects the consensus sequence for a
Sp1 binding site within a regulatory region has been
described as a good osteoporosis marker [18,19].
Allelic frequencies in the Italian population for the five
polymorphic markers cited above have been determined
already [15]. Aim of the study was to test the hypothesis of
association of these gene polymorphisms with several BMD
markers in CF patients.2. Materials and methods
2.1. Patients under study
Patients admitted to the CF Center of Verona during a one-
year periodwere asked to participate in the study. Patients were
followed by a team with specific CF care expertise, practisedregular chest physiotherapy, and followed a personalized
treatment program, including pancreatic enzyme supplemen-
tation, vitamins (1200 IU of vitamin D per day), caloric
supplementation tailored to reach the daily intake adequate for
sex and age, and per os, ev and via aerosol antibiotics.
A complete bone and CF evaluation was obtained for 82
subjects (39 males, 43 females), who were then divided in
three subgroups according to the lowest BMD T score at
lumbar spine or femur. The first group included osteoporotic
CF patients, the second osteopenic CF patients, the third CF
patients with normal bone density. All the patients in the
three groups were genotyped for polymorphic marker
analysis of the four genes under study.
Inclusion criteria were cystic fibrosis (consistent pheno-
type and positive sweat test or CFTR analysis), age equal or
above 18 years, and a written informed consent. Patients
previously treated with biphosphonates or calcitonin,
terminal patients, and pregnant women were excluded from
the study.
2.2. Bone evaluation
2.2.1. Biochemical determinations
Routine biochemical analysis for disease follow-up was
performed with automatic analyzers. Measurements includ-
ed serum calcium, phosporus, alkaline phosphatase and
creatinine concentrations. Urine was collected in 24-h pools
for calcium and creatinine. Fasting serum and urine samples
were collected in the morning (from 8:00 to 9:30 AM)
within one month of DXA scan for the assessment of bone
metabolism. Commercial kits were used for the measure-
ments of serum intact parathyroid hormone (PTH; Diag-
nostic Systems Laboratories, Nichols, CA, USA), serum 25-
hydroxy-vitamin D (25OhvitD; DiaSorin, Stillwater, MN,
USA), serum osteocalcin (OC; Incstar; Stillwater, MN,
USA), and free testosterone (Coat a Count, DPC, Los
Angeles, CA, USA). The sex and age-matched normal
ranges for all these parameters were provided by the
manufacturer of the commercial kits.
2.2.2. Fracture evaluation
49/82 patients had a spine X-ray taken because of clinical
indication. The semiquantitative method described by
Genant et al. [20] was used for assessing the prevalence
of vertebral deformities by a blinded radiologist.
2.2.3. Bone densitometry
BMD at the lumbar spine (L1–L4) and left proximal
femur were measured by the same technician in all patients
by dual-energy X-ray absorptiometry (DXA; QDR 2000,
Hologic Inc., Waltham, MA). The lumbar vertebrae with
fractures or deformities were excluded from analysis.
Quality control was maintained by daily scanning of an
anthropomorphic spine phantom. The precision is 1% in the
lumbar spine, and <1.5% for total proximal femur BMD.
Patients’ BMDs are expressed as standard deviation below
Table 1
Anthropometric and CF-associated variables in normal, osteopenic and osteoporotic patients
Group 1 normal bone
density
Group 2 osteopenia Group 3 osteoporosis Statistical
evaluation
Numerosity 15/82 46/82 21/82 –
Mean age (years) 27.73T4.19 26.71T5.93 28.1T9.51 NS
Males/females 9/6 19/27 11/10 NS
CFTR genotype F508del /UK: 3 UK/
UK: 3 F508del /
F508del: 2 F508del /
G542X: 2 F508del /
R553X: 2 1717–1G>
AvW1282X: 1 F508del /
N1303K: 1 G542X/UK: 1
F508del /F508del: 6 UK/UK: 5 F508del /
UK: 3 2183AA>G/UK: 3 2789+5G>
A /UK: 3 F508del /N1303K: 3 F508del /
R1162X: 3 F508del /2183AA>G: 2 N1303K/
N1303K: 2 R1162X/R1162X: 2 R1162X/
2183AA>G: 2 2183AA>G/G542X: 1 F508del /
1898+3A>G: 1 F508del /2789+5G>
A: 1 F508del /711+5G>A: 1 F508del /
Q353X: 1 I507del /R1162X: 1 Q552X/
UK: 1 N1303K/G542X: 1 R1162X/3849+
10KbC>T: 1 R1162X/711+5G>A: 1 T338I /
UK: 1 R553X/UK: 1
F508del /F508del: 4 F508del /
UK: 3 F508del /N1303K: 2 UK/
UK: 2 2789+5G>A/2789+5G>
A: 1 F508del /1898+3A>G: 1 F508del /
2183AA>G: 1 F508del /3849+10KbC>
T: 1 F508del /G542X: 1 F508del /
R1066H: 1 F508del /R1162X: 1 Q552X/ :
1 R352Q/ : 1 R553X/UK: 1
Weight (kg) 61.7T5.89 56.5T8.25 48.9T9.40 p <0.0001
BMI 22.6T1.3 20.3T2.7 18T2.9 p <0.0001
PS/PI 3/12 10/36 7/14 NS
FEV1% predicted 52.33T16.73 49.82T21.44 37.1T21.07 p =0.0205
NS = not significant.
PS = pancreatic sufficiency; PI = pancreatic insufficiency.
UK = unknown.
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provided by the Hologic (lumbar spine) or by the NHANES
Study [21]. When discordant results were found in spine and
femur, the lowest value was retained [22].
2.3. Phenotype evaluation and CFTR genotype
2.3.1. Respiratory parameters
Respiratory function, evaluated by forced expiratory
volume in 1 s (FEV1), by Biomedin bell spirometry
[23,24].Table 2
Bone variables in normal, osteopenic and osteoporotic patients
Group 1 norm
bone density
Numerosity 15/82
Spine T score 0.19T0.43
Femur T score 0.06T0.41
Vertebral fractures (vf) (49/82 patients)* 0 vf: 4
1 vf: 3
2 vfs: 1
3 vfs: 0
4 vfs: 0
NA.: 7
S-IgG (g/l, normal range 7.0–16) 16.03T2.55
S-ionized calcium (mmmol/l, normal range 1.10–1.35) 1.2T0.04
S-PTH (ng/l, normal range 10–65) 43.54T29.08
S-25OHvitD (nmol/l, normal range 30–150) 47.09T20.01
S-osteocalcin (nmol/l, normal range 0.8–2.2) 1.14T0.99
S-free testosterone (pg/ml, normal range 9–37 (men)) 60.21T53.4
U-calcium (mmol/24 h, normal range 1.25–6.25) 6.40T3.41
*Information on vertebral fractures were not available for 33 individuals.
.NA: data not available.2.3.2. Gastrointestinal and nutritional parameters– weight and body mass index (BMI).
– pancreatic sufficiency or insufficiency as determined by
a 72-h faecal fat, performed at the time of diagnosis,
and, in pancreatic sufficient patients, repeated from time
to time.
2.3.3. CFTR analysis
Patients selected for the study had been characterized
previously for CFTR mutations with a reverse dot blot (RDB)al Group 2
osteopenia
Group 3
osteoporosis
Statistical
evaluation
46/82 21/82 –
1.28T0.67 3.03T1.03 p <0.0001
1.51T0.57 2.95T0.60 p <0.0001
0 vf: 10 0 vf: 4 NS
1 vf: 7 1 vf: 1
2 vfs: 8 2 vfs: 4
3 vfs: 4 3 vfs: 2
4 vfs: 0 4 vfs: 1
NA: 17 NA: 9
14.97T3.86 18.10T6.33 NS
1.21T0.03 1.18T0.04 NS
40.52T27.7 32.46T20.50 NS
53.83T24.47 50.06T21.14 NS
2.04T4.32 2.38T4.24 NS
37.24T62.82 45.46T67.06 NS
5.76T2.85 6.62T3.5 NS
Table 3
CTR, ER, VDR and COL1A1 polymorphisms genotype distribution and allele frequencies
Polymorphic marker Genotype distribution (number of subjects) Allele frequencies (%)
CALCR (AluI) CC (5) CT (30) TT (47) C (24) T (76)
ESR1 (PvuII) CC (15) CT (39) TT (28) C (42) T (58)
ESR1 (XbaI) GG (6) GA (43) AA (33) G (34) A (66)
VDR (FokI) CC (28) CT (49) TT (5) C (64) T (36)
COL1A1 Sp1 (MscI/ApaI) GG (44) GT (31) TT (7) G (73) T (27)
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est CFTR mutations in North-eastern Italy (F508del, I507del,
R117H, R1162X, 2183AA>G, N1303K, 3849+10KbC>T,
G542X, 1717-1G>A, R553X, Q552X, G85E, 711+5G>A,
W1282X, 3132delTG and 2789+5G>A) [25]. Some patients
underwent a further genetic analysis. Genotypes were divided
according to classes of mutations [26], grouping together
classes I, II, and III, which are considered phenotypically more
severe, and classes IVand V, which are considered phenotyp-
ically milder.
2.4. Analysis of the genes under study
VDR/FokI RFLP: Oligonucleotide primers and amplifi-
cation conditions were as described previously [27].
ESR1/XbaI and PvuII RFLPs: Oligonucleotide primers
and amplification conditions were as described previously
[28].
CALCR/AluI RFLP was detected according to the
conditions described [14].COL1A1-Sp1 binding site G/T
dymorphism, originally described by Grant et al. [18], was
detected by using modified oligonucleotide primers and
ApaI restriction enzyme according to Moskalenko et al.
[29]. Taq DNA polymerase was purchased from GIBCO-
BRL, restriction endonucleases were purchased from New
England Biolabs. For genotypization the PCR products
were digested with an excess of the appropriate restriction
enzyme. The digestion products were resolved on 3%
agarose gels (ESR1 XbaI and PvuII, VDR FokI, and
CALCR AluI) or 6% acrylamide gels (COL1A1-Sp1), and
stained with ethidium bromide. Control individuals of
known genotypes were run in parallel in each gel. A small
number of subjects(not exceeding 10%) had to be re-
genotyped due to dubious interpretation of the electropho-
retic profile.Table 4
ESR1 PvuII and XbaI combined genotype in normal, osteopenic and
osteoporotic patients
Group 1 normal
bone density
Group 2
osteopenia
Group 3
osteoporosis
CC/GG 2 3 1
CC/GA 4 2 3
CT/GA 2 22 10
CT/AA 3 2 0
TT/AA 4 17 7
p : 0.035.For both the aforementioned genes and for CFTR
analysis, DNA was obtained from peripheral blood samples
by standard procedures.
2.5. Statistical analyses
Departure from Hardy–Weinberg (HW) equilibrium was
tested for each marker. Both quantitative and qualitative
traits were studied. Qualitative traits were studied with
contingency tables and chi2 test. The significance of the
results was estimated by permutation tests. Logistic regres-
sion models were used to study the association of binary
traits with the genetic factors and other covariates.
Quantitative traits (i.e. bone density) were studied with
multivariate analyses of variance including the relevant
covariates (es. BMI). Haplotype frequencies were estimated
with the E–M (expectation–maximization) method as
implemented in the computer program EH. The association
of a trait with haplotypes was studied through the
computation of the maximum likelihood estimates of the
haplotype frequencies and the posterior probabilities of the
pairs of haplotypes for each subject using an EM algorithm.
The glm (general linear model) function was used to
compute residuals of the regression of the trait (quantitative
or qualitative) on the non-genetic covariates. Statistical
analyses were performed using the following computer
programs or package: R (R Development Core Team
(2004), the haplo.stats library (http://cran.at.r-project.org/
src/contrib/Descriptions/haplo.stats.html, ver 1.1.1) and the
EH program (http://linkage.rockefeller.edu/ott/eh.htm).3. Results
According to femur and spine T score results, 15 patients
were considered normal (group 1), 46 osteopenic (group 2),
and 21 osteoporotic (group 3) [30]. The anthropometric andTable 5
ESR1 haplotypes and u-calcium 24 h association in phase-unknown
unrelated individuals
PvuII XbaI Hap-freq Hap-score p-val
T A 0.61207 2.60072 0.0093
C G 0.32759 1.18014 0.23794
C A 0.06034 3.06761 0.00216
Global-stat=11.978, df =2, p-val=0.00251.
Hap-score: haplo score statistics (Schaid DJ).
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between 1.5 and 2.5 osteopenic, and <2.5 osteopo-
rotic) are shown in Table 1.
No statistical difference was found among the three
groups as far as age, sex, and pancreatic status were
concerned. Nutrition, as evaluated by weight and BMI, and
pulmonary function, expressed by FEV1, scored signifi-
cantly worse in the two groups with the lowest T score
(Table 1). Long-term steroid treatments for bronchopulmo-
nary allergic aspergillosis were evenly distributed in the
groups (1/15 in group 1, 7/46 in group 2, 5/21 in group 3).
CFTR genotypes, and their distribution in the three
groups are shown in Table 1. Among the most common
mutations, R1162X and F508del were found to be more
frequent in patients with lower BMD ( p =0.044 and
p =0.071, respectively; data not shown). Genotypes grouped
according to mutation classes were evenly distributed.
Bone variables in relation to the T score are shown in
Table 2. No statistical difference was found among the three
groups in terms of vertebral fractures, nor for any of the
biochemical markers under study.
Table 3 reports the distribution of CALCR, ESR1, VDR,
and COL1A1 genotypes and allele frequencies in the sample
under study. Alleles at the five loci were distinguished and
named consequently by their polymorphic nucleotides.
Allele frequencies were comparable to those calculated in
a reference population [15,16]; the distribution of genotypes
was in agreement with the Hardy–Weinberg equilibrium for
all except the VDR/FokI polymorphism ( p =0.009).
Statistical analysis did not show any significant associ-
ation of the genotypes at the five polymorphic markers with
unadjusted or adjusted (BMI and FEV1) groups 1, 2 or 3.
The ESR1 PvuII and XbaI genotypes distribution in normal,
osteopenic and osteoporotic patients, respectively, differed
from the expected ( p =0.035) as shown in Table 4.
The analysis of the individual PvuII-XbaI haplotypes
indicates that the haplotype C–A is associated to elevated u-
calcium levels whereas the haplotype T–A is associated to
lower values (global statistics: p =0.00251) (Table 5).
Table 6 shows the estimated frequency of the ESRI PvuII
and XbaI haplotypes. The estimated frequency of T–G
haplotype is close to 0% while the expected frequency was
close to 20%. Therefore, the PvuII and XbaI markers, which
are located approximately 50 base pairs apart within intron 1
of the ESR1 gene, are in strong linkage disequilibrium.Table 6
Estimated haplotype frequency of the two ESR1 polymorphic markers
Allele at locus Allele at locus Haplotype frequency
1 (PvuII) 2 (XbaI)
Expected Observed
C A 0.276 0.081
T A 0.393 0.588
C G 0.136 0.331
T G 0.195 0
v2=85,86.4. Discussion
This study was aimed at evaluating the importance of 5
candidate gene polymorphisms in CF bone disease. We
looked for the existence of particular susceptibility geno-
types which may possibly modulate the bone phenotype in
CF. We have selected four genes which have been tested and
proven as valid candidates for BMD variation in the general
population within Caucasians [15,16].
As far as CFTR genotype/phenotype correlation is
concerned, an association between reduced BMD and
F508del, independent of respiratory, pancreatic and nutri-
tional degree of impairment, has been reported [31]. King et
al. [31] showed that in their CF population mean BMD Z
scores at both lumbar spine and femoral neck were
significantly lower in either homozygotes or heterozygotes
for the F508del mutation, compared to those who had no
F508del allele. Their suggestion that some CFTR mutations
may be associated with a reduced BMD in CF was partially
confirmed by the present study, where R1162X or F508del
alleles were found to be more frequent in patients with
lower BMD.
However, mutations in the CFTR gene are the primary,
but not the only determinants of phenotype in CF. The
variability in the spectrum of CF clinical manifestations
can be partially explained by allelic heterogeneity at the
CFTR gene locus, but there are anyway striking variations
even among CF patients with the same CFTR genotype.
Some components of the CF phenotype must be strongly
influenced by secondary factors, both genetic and
environmental.
Several studies examined modifier genes candidate for
modulating the severity of the pulmonary and gastrointes-
tinal disease manifestations [32–35]. Lung and pancreas,
however, are not the only organs involved in CF, and as the
population of patients ages, the involvement of other body
districts is on the rise. CF related bone diseases are
nowadays acknowledged as a significant clinical complica-
tion of CF. Several risk factors connected to the physiopa-
thology of CF have been identified, and, as a general rule,
the more severe the disease, the worse the bone involve-
ment. However, similarly to other clinical aspects of CF, one
could speculate that non-CFTR modifier genes may
influence the degree of bone disease, and indeed there is
some evidence supporting such hypothesis.
First, bone density is a multifactorial trait, where
inherited factors affect the variability of the phenotype. In
studies of monozygotic and dizygotic twins approximately
80% of the age-specific variation in bone mass can be
accounted for by genetic factors [36].
Second, correlations have been found between low bone
density and specific alleles of some candidate genes,
including the ones examined in this study [12–19].
Finally, preliminary results support the importance of the
genetic background for osteoporosis in another chronic
condition, thalassemia major [37,38].
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correlated with an increased risk for low bone mineral
density. Osteopenic, and even more osteoporotic CF patients
had worse pulmonary function and nutritional status
compared to the normal T score group (see Table 2).
However, genotype or haplotype distribution for the genes
under study did not differ significantly in normal, osteo-
penic and osteoporotic CF patients. It could be speculated
that the minor effect of these genes could be disguised by
the predominant CFTR gene. In other words, these genes
contribution to BMD could be difficult to evaluate in the
presence of a very strong osteoporosis-facilitating factor like
the severity of CF. In order to remove the effect of CFTR
gene, we adjusted BMD levels for BMI and FEV1, but no
significant correlation with any of the studied genotype or
haplotype was observed. It is anyway worth stressing that
the rather limited sample size, the categorization of the trait,
the variability in CF genotype and the absence of restriction
to possible BMD covariates (i.e. gender) may affect the
chance to detect association. Therefore, the present study
can not exclude that these genes may contribute to the
variability of bone phenotype in CF.
It is worth noting that combined PvuII/XbaI genotypes
at the ER locus were not distributed as expected within the
three phenotypic classes (Table 4). Previously, we had also
observed that the T–A haplotype was preferentially non
transmitted to osteopenic/osteoporotic sibs, while an
association of C–A and C–G haplotypes with low BMD
was found at the spine and femur (unpublished data).
Conversely, a retrospective meta-analysis of ESR1 associ-
ation studies in osteoporosis excluded an effect from PvuII
and XbaI markers on BMD, but suggested an association
of XbaI with vertebral fractures [13,39]. Moreover ER
haplotype C–A was found to be significantly associated
with high u-calcium level, a calcium balance marker, while
the opposite was true for the T–A haplotype (Table 5).
Recently we observed that estradiol deficiency may have a
significant role in the pathogenesis of osteoporosis in
patients with CF in both genders [40]. There is some
evidence that estrogen may have direct effects on kidneys,
besides those on bone [41]. It has been shown that, in
elderly women, estrogen deficiency may exacerbate bone
resorption by increasing renal calcium loss [42]. A reduced
effect of estrogen on renal calcium metabolism could be
relevant in CF patients, who appear to be at higher risk for
nephrocalcinosis and urolithiasis [43,44]. Further studies
on larger patient’s samples may clarify the actual role of
ESR1 in CF bone disease.
In conclusion, we looked for susceptibility alleles which
may function as modifier genes for the osteoporotic
phenotype in CF patients. No significant correlation was
found between the VDR, CALCR, and COL1A1 gene
polymorphisms and reduced BMD values in CF. ESR1 gene
variants may play a role in modulating the bone phenotype
but, on the whole, modifier genes appear to play a minor
role, if any, in the development of osteoporosis in CF.Acknowledgements
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